

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

50-780

CORRESPONDENCE

B|BRAUN

B. Braun Medical Inc.
B. Braun Medical Inc.
2525 McGaw Avenue
P.O. Box 19791
Irvine, California 92623-9791

Telephone: 949-660-2000
Fax: 949-660-2700

February 16, 2001

NEW CORRESPONDENCE


NDA 50-780, Cefuroxime for Injection USP and Dextrose Injection USP in the Duplex™ Container

Ms. Elizabeth Duvall-Miller, Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV, HFD-520
9201 Corporate Boulevard, Room 309
Rockville, Maryland 20852

Reference is made to pending New Drug Application, NDA 50-780 for Cefuroxime for Injection USP and Dextrose Injection USP in the Duplex™ Container, submitted April 17, 2000, and amended on December 21, 2000. Further reference is made to Dr. Pagay's fax dated February 16, 2001 outlining the draft regulatory specifications for the drug substance and drug product.

We have reviewed the draft regulatory specifications as outlined in the fax. They are consistent with the specifications and methods presented in the original application and subsequent amendments, and will be used as the regulatory specifications for the commercialized product.

Sincerely,



John Spoden
Associate Director, Regulatory Affairs

Desk copy: Dr. Shrikant Pagay